Barclays’s Anthera Pharmaceuticals, Inc. ANTH Stock Holding History

Barclays’s Portfolio ANTH Stock Details ANTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-105	Closed	–	–	7555
2018 Q1	$0	Buy	105 +102	+3,400%	+$152	﹤0.01%	7566
2017 Q4	$0	Sell	3 -48	-94%	-$83	﹤0.01%	7289
2017 Q3	$0	Buy	51 +48	+1,600%	+$68	﹤0.01%	7230
2017 Q2	$0	Sell	3 -3,991	-100%	-$8.95K	﹤0.01%	7159
2017 Q1	$14K	Buy	3,994 +3,827	+2,292%	+$18.1K	﹤0.01%	5968
2016 Q4	$0	Buy	167 +136	+439%	+$2.35K	﹤0.01%	7011
2016 Q3	$1K	Sell	31 -38	-55%	-$958	﹤0.01%	6531
2016 Q2	$2K	Sell	69 -2,238	-97%	-$63.2K	﹤0.01%	6024
2016 Q1	$55K	Buy	2,307 +593	+35%	+$16.1K	﹤0.01%	4707
2015 Q4	$55K	Buy	1,714 +438	+34%	+$19.3K	﹤0.01%	4741
2015 Q3	$61K	Buy	1,276 +1,190	+1,384%	+$83.1K	﹤0.01%	4914
2015 Q2	$5K	Buy	+86	New	+$3.98K	﹤0.01%	6509

Other funds holding ANTH

Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Barclays's ANTH Position: Q2 2018 in Review

Barclays sold out of Anthera Pharmaceuticals, Inc. (ANTH) in Q2 2018, closing a stake of 105 shares.

Barclays first reported a position in ANTH in Q2 2015 and held it in 12 quarters. The position peaked at $61K in Q3 2015. 5 funds tracked by Wall St. Rank hold ANTH as of Q2 2018.

Barclays reported no remaining Anthera Pharmaceuticals, Inc. position as of Q2 2018 after selling out during the quarter.
Barclays sold 105 Anthera Pharmaceuticals, Inc. shares in Q2 2018.
Barclays first reported a position in Anthera Pharmaceuticals, Inc. in Q2 2015 and held it in 12 quarters.
Barclays's Anthera Pharmaceuticals, Inc. position peaked at $61K in Q3 2015.
5 funds tracked by Wall St. Rank held Anthera Pharmaceuticals, Inc. as of Q2 2018.

Based on Barclays's 13F filing for Q2 2018, filed 14 Aug 2018.